Your fact-checks will appear here
If PSA rises while imaging shows no visible cancer, clinicians usually confirm the trend, measure PSA doubling time, and may choose closer monitoring, targeted imaging/biopsy or systemic therapy depen...
The American Urological Association (AUA) and the European Association of Urology (EAU) continue to anchor the clinical definition of biochemical recurrence (BCR) after radical prostatectomy at a PSA ...
Salvage radiotherapy (SRT) works best when PSA is low: multiple guideline reviews and cohort studies show improved biochemical-relapse–free and metastasis-free survival when SRT is given at lower PSA ...
Most clinical guidelines and long‑standing studies define biochemical recurrence (BCR) after radical prostatectomy (RP) as a confirmed PSA ≥0.2 ng/mL, usually with a second confirmatory value >0.2 ng/...
PSA doubling time (PSADT) and PSA velocity (PSAV) are established prognostic markers used to time salvage therapy: short PSADT — commonly <6–12 months — signals higher risk of metastasis and is cited ...
PSA level behavior after definitive prostate cancer treatment is an early, widely used signal of biochemical recurrence (BCR), and certain PSA patterns — especially short PSA doubling time (≤5 months)...
Multiple retrospective studies and guideline discussions report that short PSA doubling time (PSADT) and high PSA velocity (PSAV) are associated with higher risks of metastasis and prostate-cancer–spe...
Current first-line approaches to biochemical recurrence (BCR) after radical prostatectomy (RP) center on risk-directed evaluation with PSMA-PET imaging and early salvage radiotherapy (sRT) to the pros...